Biotalys Expands Its Intellectual Property with New Patents
Biotalys, a company specializing in Agricultural Technology and sustainable crop protection, has recently taken a big step forward by securing patents for its groundbreaking biofungicide, EVOCA. This achievement has been acknowledged by both the European Patent Office and the United States Patent and Trademark Office, marking a pivotal moment for the company.
CEO’s Thoughts on Patent Accomplishments
Kevin Helash, the Chief Executive Officer, shared his pleasure regarding the patent approvals, noting the thorough evaluation process that led to this significant recognition. He commented, “These decisions affirm the innovative aspects of our protein-based biocontrol candidate, EVOCA. They provide Biotalys with the exclusivity needed to collaborate with commercial partners, allowing for the efficient production and distribution of EVOCA in Western markets.”
Looking Beyond U.S. and Europe for Patent Protection
Biotalys isn't just targeting Europe and the U.S. for its patent goals. The company is actively seeking patent protection for EVOCA’s active ingredient in several other countries, including Argentina, Brazil, and South Africa. These regions represent sizable opportunities in the agricultural field. By building a strong portfolio across different jurisdictions, Biotalys is strategically positioning itself within the crop protection industry.
What Makes EVOCA Unique
EVOCA is distinguished as a novel protein-based biofungicide that introduces a new resistance classification, demonstrating its ability to effectively manage fungal diseases that impact fruits and vegetables. It has shown impressive results in trials, proving its effectiveness across various conditions. Currently, EVOCA is undergoing regulatory review by the U.S. Environmental Protection Agency and the Dutch College voor Toelating van Gewasbeschermingsmiddelen en Biociden, aiming for a rapid market entry.
Looking Ahead: EVOCA NG
The success of EVOCA is setting the stage for another exciting product, EVOCA NG, which is anticipated to be Biotalys’ first fungicide derived from its AGROBODY technology platform. Both EVOCA and EVOCA NG share the same active ingredient, which is now protected by the recently granted patents.
About Biotalys
Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021. The company focuses on developing protein-based biocontrol solutions intended to replace traditional chemical pesticides. With a commitment to improving food safety and sustainability, Biotalys continues to innovate in the agricultural space.
Contact Details for Biotalys
If you need more information about Biotalys or its products, please contact:
Toon Musschoot, Head of Investor Relations and Communications
T: +32 (0)9 274 54 00
E: IR@biotalys.com
Frequently Asked Questions
What is EVOCA?
EVOCA is an innovative protein-based biofungicide developed by Biotalys to tackle fungal diseases in crops, particularly fruits and vegetables.
Which markets have approved the EVOCA patents?
The patents for EVOCA have been granted in both Europe and the United States, which broadens its market access.
What future products does Biotalys plan to introduce after EVOCA?
Biotalys intends to launch EVOCA NG, which shares the same active ingredient as EVOCA and is derived from its AGROBODY technology platform.
How does Biotalys contribute to sustainability in agriculture?
By creating alternatives to traditional chemical pesticides, Biotalys aspires to foster safer and more sustainable agricultural practices through its biocontrol solutions.
Where can I find more details about Biotalys?
You can find more information about Biotalys and its initiatives on the company's official website.
